Syncona chief investment officer Chris Hollowood (Syncona)
Syncona launches new gene therapy player Purespring, spun out of the University of Bristol, with a roughly $60M Series A
Longtime UK life sciences investor Syncona has a new gene therapy outfit, one that the firm says is one of the first ever to focus …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
